Atea Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $434.5M
- Price
- $5.43
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.31%
- Volume
- 209.9K
About
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Quick stats
Shares outstanding80.0M
Computed float60.5M
Float / shares75.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001593899
Websitehttps://www.ateapharma.com
AI Summary
AI-generated1/15
majorbullishearnings
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Atea reported cash and investments of $219.5 million at the end of Q2 2026, down from $301.8 million at year-end 2025, with a net loss of $0.41 per share for the quarter.
The company provided an update on its Phase 3 C-BEYOND trial, where BEM/RZR achieved a 93.9% sustained virologic response rate, meeting the primary endpoint of non-inferiority compared to Epclusa. Atea plans to submit a New Drug Application to the FDA in the second quarter of 2027.
Pipeline progress includes completion of enrollment in the C-FORWARD Phase 3 trial, with topline results expected in early Q1 2027, and the initiation of a Phase 1 trial for AT-587 for the treatment of Hepatitis E.
Red flags
- Cash position decreased by $82.3 million in six months, indicating a burn rate that will require continued funding or success near the NDA timeline.